Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$50.50 USD
+0.31 (0.61%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $50.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Apogee Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | NA | NA | NA |
Cost Of Goods | 0 | 0 | NA | NA | NA |
Gross Profit | 0 | 0 | NA | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 93 | 31 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -93 | -31 | 0 | 0 | 0 |
Non-Operating Income | 9 | 0 | NA | NA | NA |
Interest Expense | 0 | 9 | NA | NA | NA |
Pretax Income | -84 | -40 | NA | NA | NA |
Income Taxes | 0 | 0 | NA | NA | NA |
Minority Interest | 0 | 0 | NA | NA | NA |
Investment Gains/Losses | 0 | 0 | NA | NA | NA |
Other Income/Charges | 0 | 0 | NA | NA | NA |
Income From Cont. Operations | -84 | -40 | NA | NA | NA |
Extras & Discontinued Operations | 0 | 0 | NA | NA | NA |
Net Income (GAAP) | -84 | -40 | NA | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -96 | -31 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | -3 | 0 | NA | NA | NA |
Income After Depreciation & Amortization | -93 | -31 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 25.01 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.36 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -3.36 | -16.16 | NA | NA | NA |
Fiscal Year end for Apogee Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 38.19 | 37.15 | 24.31 | 18.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -38.19 | -37.15 | -24.31 | -18.89 |
Non-Operating Income | NA | 6.09 | 5.42 | 3.47 | 0.00 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -32.09 | -31.74 | -20.84 | -18.89 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -32.09 | -31.74 | -20.84 | -18.89 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -32.09 | -31.74 | -20.84 | -18.89 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 50.19 | 25.01 | 41.23 | 5.00 |
Diluted EPS Before Non-Recurring Items | NA | -0.64 | -0.32 | -0.51 | -3.78 |
Diluted Net EPS (GAAP) | NA | -0.64 | -0.32 | -0.51 | -3.78 |